Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)

被引：0

作者：

Turner, Nicolas ^{[1
,2
]}

Jhaveri, Komal ^{[3
]}

Kalinsky, Kevin ^{[4
]}

Loibl, Sibylle ^{[5
]}

Loi, Sherene ^{[6
]}

Im, Seock-Ah ^{[7
]}

Saura, Cristina ^{[8
]}

Schmid, Peter ^{[9
]}

Schutzman, Jennifer L. ^{[10
]}

Stout, Thomas J. ^{[11
]}

Lei, Guiyuan ^{[12
]}

Hutchinson, Katherine E. ^{[13
]}

Thanopoulou, Eirini ^{[14
]}

Juric, Dejan ^{[15
]}

机构：

[1] Royal Marsden Hosp, London, England

[2] Inst Canc Res, London, England

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Mem Hosp, 1275 York Ave, New York, NY 10021 USA

[4] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY USA

[5] GBG Forschungs GmbH, Med & Res, Neu Isenburg, Germany

[6] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia

[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[8] Vall dHebron Inst Oncol VHIO, Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[9] Canc Res UK Barts Ctr, Ctr Expt Canc Med, London, England

[10] Genentech Inc, gRED Genentech Res & Early Dev, San Francisco, CA 94080 USA

[11] Genentech Inc, Oncol, Prod Dev, San Francisco, CA 94080 USA

[12] Roche Prod Ltd, Biometr, Welwyn Garden City, Herts, England

[13] Genentech Inc, Oncol Biomarkers, San Francisco, CA 94080 USA

[14] Genentech Inc, Prod Dev, Oncol, Welwyn Garden City, Herts, England

[15] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT-36-01

引用

页数：1

共 50 条

[21] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
Mayer, Erica L.
Tolaney, Sara M.
Brufsky, Adam
Gradishar, William John
Jhaveri, Komal L.
Martin, Miguel
Moscetti, Luca
Schneeweiss, Andreas
Vidal, Gregory A.
Cortazar, Patricia
Feldman, Merilin
Day, Bann-mo
Rugo, Hope S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC).
Bedard, Philippe L.
Accordino, Melissa Kate
Cervantes, Andres
Gambardella, Valentina
Hamilton, Erika P.
Italiano, Antoine
Juric, Dejan
Kalinsky, Kevin
Krop, Ian E.
Oliveira, Mafalda
Saura, Cristina
Schmid, Peter
Turner, Nicholas C.
Varga, Andreea
Shankar, Noopur
Schutzman, Jennifer
Royer Joo, Stephanie
Martin, Miguel Valero
Jhaveri, Komal L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole plus palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2-LA/mBC).
Turner, Nicholas C.
Jhaveri, Komal L.
Bardia, Aditya
Niikura, Naoki
Dieras, Veronique
Barrios, Carlos H.
Im, Seock-Ah
Mueller, Volkmar
Bellet, Meritxell
Chang, Ching-Wei
Ross, Graham A.
Patre, Monika
Loi, Sherene
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
Rugo, H.
Tolaney, S.
Dickler, M.
Kabos, P.
Ho, C-L
Wildiers, H.
Jerusalem, G.
Ales-Martinez, J. E.
Hossain, A.
Johnston, E.
Gianni, L.
[J]. CANCER RESEARCH, 2017, 77
[25] persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole plus palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2-LA/mBC)
Mueller, Volkmar
Turner, Nicholas
Jhaveri, Komal
Bardia, Aditya
Niikura, Naoki
Dieras, Veronique
Barrios, Carlos
Im, Seock-Ah
Bellet, Meritxell
Chang, Ching-Wei
Ross, Graham
Patre, Monika
Loi, Sherene
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 25 - 25
[26] Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2-LA/mBC)
Turner, Nicolas C.
Loi, Sherene
Moore, Heather M.
Chang, Ching-Wei
Eng-Wong, Jennifer
Bardia, Aditya
Boni, Valentina
Sohn, Joohyuk
Jhaveri, Komal L.
Lim, Elgene
[J]. CANCER RESEARCH, 2022, 82 (04)
[27] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Walker, Amanda J.
Wedam, Suparna
Amiri-Kordestani, Laleh
Bloomquist, Erik
Tang, Shengui
Sridhara, Rajeshwari
Chen, Wei
Palmby, Todd R.
Zirkelbach, Jeanne Fourie
Fu, Wentao
Liu, Qi
Tilley, Amy
Kim, Geoffrey
Kluetz, Paul G.
McKee, Amy E.
Pazdur, Richard
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
[28] A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2-breast cancer
Jhaveri, Komal
Kalinsky, Kevin
Bedard, Philippe
Cervantes, Andres
Saura, Cristina
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Gambardella, Valentina
Veitch, Zachary
Oliveira, Mafalda
Dickmann, Leslie
Kotani, Naoki
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Juric, Dejan
[J]. CANCER RESEARCH, 2020, 80 (04)
[29] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Dickler, Maura N.
Saura, Cristina
Richards, Donald A.
Krop, Ian E.
Cervantes, Andres
Bedard, Philippe L.
Patel, Manish R.
Pusztai, Lajos
Oliveira, Mafalda
Cardenas, Alison K.
Cui, Na
Wilson, Timothy R.
Stout, Thomas J.
Wei, Michael C.
Hsu, Jerry Y.
Baselga, Jose
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
[30] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
Tajiri, Wakako
Nakamura, Yoshiaki
Kawasaki, Junji
Koi, Yumiko
Akiyoshi, Sayuri
Koga, Chinami
Tokunaga, Eriko
[J]. CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →